Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biden’s HHS Pick Sought ‘March In’ Rights For Veklury; Targeted AbbVie ‘Pay For Delay’ Tactics

Executive Summary

California attorney general Xavier Becerra has sought to lower drug prices in California as part of a broader focus on health care costs, an approach he may bring to a new role in the Biden Administration.

You may also be interested in...



Six Glocal Trends That Could Lift Or Drift India Pharma In 2021

Scrip takes a look at the key trends that could play out in 2021 to shape the trajectory of Indian drug makers, including evolving dynamics in the US under a new president. Thorny India-China relations will add a layer of complexity, while firms may also want to look beyond the chief information officers as they ramp up digital engagement.

Trump Warns That US May Use Defense Production Act To Ensure COVID-19 Vaccine Supply

President’s comments follow two revelations: Pfizer’s acknowledgement that it will not meet its previously-stated vaccine production goals for 2020, and the US government’s decide to pass on additional Pfizer doses which have since been allocated to other countries.

Biden’s Pick Of Becerra To Lead HHS Puts Focus On Affordable Care Act

California attorney general Xavier Becerra, who has lead the blue-state legal defense of Obamacare, is among the nominees for Biden's health care team announced on 7 December, including Rochelle Walensky for CDC director. Missing from the list, though, is a nominee for FDA commissioner or CMS administrator.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel